Literature DB >> 10671607

Cerebellar and frontal lobe hypoplasia in fetuses with trisomy 21: usefulness as combined US markers.

T C Winter1, A A Ostrovsky, C A Komarniski, S B Uhrich.   

Abstract

PURPOSE: To confirm that cerebellar hypoplasia is ultrasonographically recognizable in second-trimester fetuses with Down syndrome and determine whether the combination of frontal lobe shortening and cerebellar hypoplasia is superior to either measurement alone as a marker of this abnormality.
MATERIALS AND METHODS: The frontothalamic distance (FTD) and transcerebellar diameter (TCD) were measured in 52 middle-trimester fetuses with euploid karyotypes and in 52 fetuses with Down syndrome. Receiver operating characteristic (ROC) curves were constructed with various thresholds for observed-to-expected ratios (O/Es) of the FTD, TCD, and average of these two parameters.
RESULTS: The area under the average ROC curve, 0.80, was greater than that for either the FTD alone (0.75) or the TCD alone (0.76). At a 6% false-positive rate, the sensitivity for the detection of Down syndrome obtained with the average parameter was 34% better than that obtained with only the FTD and 12% better than that obtained with only the TCD. With an O/E threshold of 0.92 for the average parameter, an odds ratio of 16.3 and positive predictive value of 12.7% in the high-risk population were achieved.
CONCLUSION: Although both measurements are individually statistically significant, the combination of TCD and FTD measurements may be superior to the use of either parameter alone as a marker of trisomy 21.

Entities:  

Mesh:

Year:  2000        PMID: 10671607     DOI: 10.1148/radiology.214.2.r00fe40533

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome.

Authors:  Ananya Mitra; Martina Blank; Daniel V Madison
Journal:  Brain Res       Date:  2012-01-03       Impact factor: 3.252

2.  Anterior-posterior thigh diameter measured by two-dimensional sonography: indicator of fetal age at 18 to 28 weeks gestation ?

Authors:  Saad R I Al-Kubaisi
Journal:  Sultan Qaboos Univ Med J       Date:  2006-12

3.  The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome.

Authors:  Faycal Guedj; Jeroen L A Pennings; Millie A Ferres; Leah C Graham; Heather C Wick; Klaus A Miczek; Donna K Slonim; Diana W Bianchi
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

4.  Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome.

Authors:  Chelsee A Hewitt; King-Hwa Ling; Tobias D Merson; Ken M Simpson; Matthew E Ritchie; Sarah L King; Melanie A Pritchard; Gordon K Smyth; Tim Thomas; Hamish S Scott; Anne K Voss
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

5.  Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome.

Authors:  A Contestabile; T Fila; A Cappellini; R Bartesaghi; E Ciani
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

Review 6.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

Review 7.  The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.

Authors:  Andrea Contestabile; Salvatore Magara; Laura Cancedda
Journal:  Front Cell Neurosci       Date:  2017-03-07       Impact factor: 5.505

Review 8.  Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?

Authors:  Laura Reiche; Patrick Küry; Peter Göttle
Journal:  Cells       Date:  2019-12-07       Impact factor: 6.600

9.  Longitudinal neuroanatomical and behavioral analyses show phenotypic drift and variability in the Ts65Dn mouse model of Down syndrome.

Authors:  Patricia R Shaw; Jenny A Klein; Nadine M Aziz; Tarik F Haydar
Journal:  Dis Model Mech       Date:  2020-09-25       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.